Dreikorn Mirjam, Milacic Zeljko, Pavlovic Vladimir, Meuth Sven G, Kleinschnitz Christoph, Kraft Peter
Department of Neurology, Hospital Main-Spessart, Lohr, Germany.
Department of Neurology, University Hospital Münster, Münster, Germany.
Ther Adv Neurol Disord. 2018 Apr 20;11:1756286418770626. doi: 10.1177/1756286418770626. eCollection 2018.
'Thromboinflammation' describes a novel concept in stroke pathophysiology that has opened up the possibility of immunotherapeutic approaches which could become promising strategies for targeted stroke therapies in the future.
We reviewed current evidence for agents approved for multiple sclerosis in preclinical and clinical stroke studies. A systematic review was performed in accordance with the PRISMA statement, searching MEDLINE, the Cochrane Central Register of Controlled Trials, and reference lists of articles published until 16 October 2017.
The review included 52 of 629 identified studies, consisting of 5 clinical and 47 preclinical trials. Most of the studies showed beneficial effects of the evaluated immunotherapeutic drugs in terms of reduction in morphological lesion size and improvement in functional outcome. Nevertheless, the significance of these findings is limited due to the high degree of heterogeneity.
Immunotherapy of stroke might be effective and could become a promising treatment strategy, but larger clinical trials with standardized interventions and outcome measures are needed.
“血栓炎症”描述了中风病理生理学中的一个新概念，这为免疫治疗方法开辟了可能性，未来可能成为有前景的针对性中风治疗策略。
我们回顾了在临床前和临床中风研究中被批准用于多发性硬化症的药物的现有证据。根据PRISMA声明进行了系统综述，检索了MEDLINE、Cochrane对照试验中央注册库以及截至2017年10月16日发表的文章的参考文献列表。
该综述纳入了629项已识别研究中的52项，包括5项临床试验和47项临床前试验。大多数研究表明，所评估的免疫治疗药物在减少形态学病变大小和改善功能结局方面具有有益效果。然而，由于高度异质性，这些发现的意义有限。
中风的免疫治疗可能有效，并且可能成为一种有前景的治疗策略，但需要进行更大规模的临床试验，采用标准化的干预措施和结局指标。
